CoMentis and Astellas : Alzheimer’s Disease Research at International Conference on Alzheimer’s Disease (ICAD)

July 28, 2008 – CoMentis, Inc. and Astellas Pharma, Inc. announced that the companies will present six abstracts related to CTS21166 (ASP1702), a beta-secretase inhibitor for the treatment of Alzheimer’s disease, at the 2008 International Conference on Alzheimer’s Disease (ICAD) in Chicago, July 26-31. CTS21166 (ASP1702) is the first of several highly selective, potent and orally active beta-secretase inhibitors being developed by CoMentis and Astellas...

...
-Single Dose Administration of the β-secretase Inhibitor CTS21166 (ASP1702) Reduces Plasma Aβ40 in Human Subjects
Poster #: P4-422

-Phase 1 Safety and Pharmacokinetic Profile of Single Doses of CTS21166 (ASP1702) in Healthy Males
Poster #: P4-454

-Pharmacokinetic / Pharmacodynamic Analysis of Plasma Aβ40 Reduction in Human Subjects Produced by the β-secretase Inhibitor CTS21166 (ASP1702)
Poster #: P4-455

-BACE1 Inhibitor CTS21166 (ASP1702) Penetrates Brain and Reduces Aβ Pathology in a Transgenic Mouse Model of Advanced AD
Poster #: P4-456

-Pharmacological Profile of BACE1 Inhibitor CTS21166 (ASP1702)
Poster #: P4-457

-Oral Administration of the BACE1 Inhibitor CTS21166 (ASP1702) Improves Cognition and Reduces Brain Aβ in Tg2576 Transgenic Mice
Poster #: P4-458

... CoMentis' Press Release -

Astellas and CoMentis : Agreement to Collaborate on the Research, Development and Commercialization of Beta-Secretase Inhibitors

April 25, 2008 – Astellas Pharma, Inc. and CoMentis, Inc. announced today that the companies have entered into an exclusive worldwide collaboration agreement to develop and commercialize products from CoMentis’ beta-secretase inhibitor program, including CoMentis’ lead candidate compound CTS-21166, an orally bioavailable, small-molecule beta-secretase inhibitor which is being developed as a disease-modifying treatment for Alzheimer’s disease. The agreement also includes a research collaboration to develop additional beta-secretase inhibitors... CoMentis' Press Release - [PDF] Astellas Pharma's Press Release -

CoMentis , Proof-of-Activity-Data from its Phase I Study of Disease-Modifying Alzheimer’s Disease Therapy

January 7, 2008 – CoMentis, Inc., a privately held biopharmaceutical company, announced that it has completed a Phase I study of its proprietary, orally bioavailable, small-molecule beta-secretase inhibitor, CTS-21166, which is being developed as a disease-modifying treatment for Alzheimer’s disease... CoMentis' Press Release-